Loading…
Employees: 808
Size MiMedx (MDXG) is a United States Health Care company (Medical Specialties) with a market value of $483M, the 2723rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $3.31 on 6 Nov 2026.
Performance Over six months the shares fell 8.1%, against -13.4% for the median peer and -1.1% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue fell 22.8% over the last twelve months (peer median +1.7%); the operating margin is -8.3% (peer median 4.4%).
Valuation It trades at 59.1× forward earnings against a peer median of 16.3× (most expensive of 9).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 32.7 points below its cost of capital (10.7% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $304M | $419M | $349M | $321M | $268M |
| Revenue growth | — | +20% | +9% | +20% | — |
| Gross profit | $234M | $344M | $287M | $265M | $217M |
| EBITDA | -$17.3M | $78.8M | $62.4M | $40.5M | -$10.7M |
| Net income | -$19.2M | $48.6M | $42.4M | $58.2M | -$30.2M |
| Free cash flow | $19.0M | $73.0M | $64.5M | $24.8M | -$19.4M |
| Capital expenditure | $3.81M | $3.12M | $1.72M | $2.15M | $2.68M |
| Total debt | $0 | $22.5M | $24.8M | $50.5M | $52.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MDXG | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -28.4% | -4.6% | lowest of 21 |
| 6-month return | -8.1% | -13.4% | 9th highest of 21 |
| Distance from 52-week high | -58.2% | -32.8% | lowest of 21 |
| Revenue growth (TTM) | -22.8% | +1.7% | 3rd lowest of 21 |
| Operating margin | -8.3% | 4.4% | 7th lowest of 21 |
| Forward P/E | 59.1× | 16.3× | most expensive of 9 |
| Growth the price implies (Req g, 7 yrs) | 11.5% | 12.5% | 7th least demanding of 13 |
| Growth delivered (Del g) | +11.0% | +1.3% | 4th highest of 13 |
| Hurdle (Req g minus delivered) | +0.5 pp | +6.7 pp | 5th least demanding of 13 |
| ROIC minus cost of capital | -32.7 pp | -3.0 pp | 2nd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| MiMedx MDXG | United States | $483M | -8% | -23% | -8% | 59.1× | 11.5% | +11.0% |
| Beijing Leadman Biochemistry 300289.SZ | China | $483M | -11% | -6% | -12% | n/a | 35.5% | -6.9% |
| CellaVision CEVI.ST | Sweden | $485M | +68% | +2% | 23% | 31.8× | 6.5% | +10.0% |
| WELL LEAD MEDICAL 603309.SS | China | $486M | -19% | +1% | 15% | 12.2× | -5.6% | +7.7% |
| China Isotope & Radiation 1763.HK | Hong Kong | $478M | -38% | -5% | 13% | 6.7× | n/a | n/a |
| Shofu 7979.T | Japan | $475M | +27% | +7% | 14% | 12.2× | n/a | n/a |
| Shanghai Kindly Enterprises Development 603987.SS | China | $474M | -14% | 0% | 11% | n/a | 3.8% | -2.8% |
| Guangdong Shirongzhaoye 002016.SZ | China | $473M | -28% | -31% | 3% | n/a | 22.2% | -11.7% |
| AngioDynamics ANGO | United States | $493M | +5% | +8% | -6% | n/a | n/a | n/a |
| Revenio REG1V.HE | Finland | $494M | -22% | +16% | 14% | 18.5× | 19.3% | +12.4% |
| Huaren Pharmaceutical 300110.SZ | China | $472M | -16% | -3% | 6% | n/a | 6.7% | +0.3% |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $471M | +40% | +5% | 11% | 38.6× | 22.1% | +2.2% |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $470M | +35% | -5% | 2% | n/a | 42.6% | +0.4% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $499M | -14% | -9% | -51% | n/a | n/a | n/a |
| Jenscare Scientific 9877.HK | Hong Kong | $463M | -32% | +993% | -106% | n/a | n/a | n/a |
| AVITA Medical RCEL | United States | $513M | +304% | +1% | -47% | n/a | n/a | n/a |
| Eiken Chemical 4549.T | Japan | $454M | -29% | +4% | 6% | 23.6× | n/a | n/a |
| Hunan Sundy Science and Technology 300515.SZ | China | $453M | -13% | +10% | 27% | 14.1× | 0.9% | +15.6% |
| Delcath Systems DCTH | United States | $518M | +30% | +36% | -2% | n/a | 10.1% | +120.2% |
| Guangdong Biolight Meditech 300246.SZ | China | $519M | -23% | +4% | -9% | n/a | 14.8% | -4.7% |
| PROTEINA 468530.KS | South Korea | $450M | -2% | -59% | -1,178% | n/a | n/a | n/a |